Alnylam (ALNY) announced full year 2026 combined net product revenue guidance for AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO of $4.9B-$5.3B, representing 71% growth compared to 2025 at the mid-point of the guidance range. On a franchise level, the guidance is as follows: Total TTR (AMVUTTRA & ONPATTRO): $4.4B-$4.7B, representing 83% growth compared to 2025 at the mid-point of the guidance range. Total Rare (GIVLAARI & OXLUMO): $500M-$600M, representing 10% growth compared to 2025 at the mid-point of the guidance range. In addition, the company plans to file Investigational New Drug applications for three to four new Alnylam-led programs by the end of 2026. The company intends to achieve the following by the end of 2030: Deliver 2+ new transformative medicines beyond TTR with blockbuster potential; Expand to 10 tissue types and greater than40 clinical programs; Achieve 25%+ total revenue CAGR through year-end 2030; Deliver 30% non-GAAP operating margin.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target lowered to $530 from $535 at Truist
- Alnylam assumed with an Outperform at Oppenheimer
- Alnylam price target lowered to $491 from $525 at Bernstein
- Alnylam: Buy Rating Reaffirmed as Long-Term TTR Growth and Strategic Update Offset Near-Term Amvuttra Launch Concerns
- Alnylam to invest $250M to expand manufacturing facility in Massachusetts